Cost-Effectiveness Studies in Oncology
The number of new drugs approved for cancer treatment is increasing every year. Several factors, such as development costs and commercial issues, make the price of new drugs higher than the price of previously launched drugs. Moreover, expenses in cancer treatment have increased more than inflation and household incomes. Consequently, there is a risk of cancer treatment becoming unsustainable in society. Therefore, cost-effectiveness analyses are very important to help physicians and policy makers to choose the best treatment for the individual who will benefit most. Economic studies involve a comparison of the costs and benefits of alternative treatment options. Cost-effectiveness studies must include a clear specification of the research question. In addition, cost-effectiveness studies must be transparent and reproducible. Physicians need to be able to understand and critically assess the quality of a pharmacoeconomic study. In this review, we will discuss how the cost of cancer care can be studied and how the data can be applied in oncology to guide health policy decisions.
KeywordsCost-effectiveness Pharmacoeconomics Health technology assessment
- 1.Howlader N, Noone A, Krapcho M, et al. Cancer statistics review, 1975–2013. National Cancer Institute. https://seer.cancer.gov/csr/1975_2013/. Published 2016. Accessed 10 July 2017.
- 2.IARC. Fact Sheets by population. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 July 2016.
- 3.American Cancer Society. The global economic cost of cancer 2010:12. http://www.cancer.org/acs/groups/content/@internationalaffairs/documents/document/acspc-026203.pdf. Accessed 12 Sept 2016.
- 5.Brazilian Court of Auditors. National Policies for Cancer Care. 2011:132.Google Scholar
- 9.Gudex C, Kind P. The Qaly tool kit. New York: Centre for Health Economics, University of York; 1988.Google Scholar
- 13.Jang RW, Le Maître A, Ding K, et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol. 2009;27(26):4268–73. https://doi.org/10.1200/JCO.2008.20.5815.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Prasad V, Jesús KD, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017. https://doi.org/10.1038/nrclinonc.2017.31.
- 18.Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473–81. http://www.ncbi.nlm.nih.gov/pubmed/1306034. Accessed 24 Mar 2017PubMedPubMedCentralGoogle Scholar